课题基金 / 基金详情

Glycolipid Immunostimulants, A symposium at the American Chemical Soc. meeting, Boston 2015

Glycolipid Immunostimulants, A symposium at the American Chemical Soc. meeting, Boston 2015
糖脂免疫刺激剂,美国化学学会研讨会。
批准号:
1515214
负责人:
Richard Franck
金额:
$0.5万
依托单位:
依托单位国家:
美国
项目类别:
Standard Grant
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-08-15 至 2017-07-31

项目摘要

项目成果

Richard Franck的其他基金

相似基金

相关文献

中文摘要
翻译
“糖脂免疫刺激剂”是一个研讨会将在波士顿举行的2015年美国化学学会全国会议。20年前,科学家们从冲绳海绵中分离出了一个小家族的半乳糖神经酰胺(Galcers)。令人惊讶的是,Galcers刺激哺乳动物的免疫系统。2015年研讨会的短期目标是让100-150名与会者就理想的糖脂免疫刺激剂(可能是Galcer变体)的设计和合成交换意见。长期目标是更详细地了解这一重要生命过程的化学过程。讲座/讨论的形式将汇集了大多数化学家谁合成了几十个小分子糖脂配体的海绵材料的启发。为期一天的会议计划举办14场讲座。每堂课之后都有一个讨论时间。这是有史以来第一次主要的研讨会,重点是设计和合成对糖脂免疫途径至关重要的配体。这次研讨会将促进智力交流,这将可能导致朝着提高配体的可用性,以精确控制免疫系统的进展。一个国际化学家小组与免疫学家之间的开放式思想交流也是一个好处。思想交流将加强美国的科学理想。自由、开放和不受约束的研究是科学造福社会的前进方向。自从最初观察到海绵糖脂的免疫刺激作用以来,其迷人的分子生物学已经被阐明。糖脂充当“关键”,其将抗原呈递细胞(APC)表面上的受体连接到自然杀伤T细胞(NKT)上的受体。当APC-糖脂-NKT的三元复合物形成时,细胞因子的爆发增强了最终免疫防御的信号。在合成化学家设计和合成母体海绵Galcer类似物的最初十几年里,研究计划主要是经验性的。配体与2种蛋白受体相互作用的结构特征尚未确定。2007年,三元配合物的X射线结构终于被报道。因此,化学家们有可能将观察到的氢键和货车德瓦耳斯排斥结合在配合物中,作为新配体设计的一部分。最终目标是获得有利于诱导一种细胞因子的配体。在撰写本文时,尚不了解观察到的结合和/或排斥效应中的哪一种对哪种细胞因子具有决定性作用。专题讨论会讨论的一个计划成果是更好地了解这些细节。
英文摘要
"Glycolipid Immunostimulants" is a symposium to be held at the Boston 2015 National Meeting of the American Chemical Society. The founding discovery leading to the titled symposium occurred 20 years ago when scientists isolated a small family of galactosylceramides (Galcers)from an Okinawan sponge. Surprisingly, Galcers stimulate mammalian immune systems. The short-term objective of the 2015 symposium is for the 100-150 participants to exchange ideas about the design and synthesis of the ideal glycolipid immunostimulant (probably a Galcer variant). The longer-term goal is to achieve a more detailed understanding of the chemistry of this significant life process. The lecture/discussion format will bring together a majority of the chemists who have synthesized the dozens of the small molecule glycolipid ligands inspired by the sponge material. There are 14 lectures planned for the one-day session. Each lecture is followed by a discussion period. This is the first-ever major symposium where the focal point is design and synthesis of ligands that are crucial for the glycolipid-based immune pathway. This symposium will foster the intellectual exchanges that will likely induce progress toward enhancing the availability of ligands for exquisite control of the immune system. The open exchange of ideas among an international group of chemists who will then interact with immunologists is also a benefit. The idea exchange will reinforce the American science ideal. Free, open and unfettered research is the way forward for science to benefit society.Since the initial observations of the immunostimulatory effect of the sponge glycolipids, their fascinating molecular biology has been elucidated. The glycolipid acts as a "linchpin" which connects a receptor on the surface of antigen-presenting cells (APC) to a receptor on natural killer T cells (NKT). When the ternary complex of APC-glycolipid-NKT is formed, a burst of cytokines ensues which signals for the ultimate immune defense. For the first dozen years of work by synthetic chemists to design and synthesize analogs of the parent sponge Galcer, the research plan was largely empirical. The structural features of the interaction of the ligand with the 2 protein receptors had not been defined. In 2007, the X-ray structure of the ternary complex was finally reported. Thus, it has become possible for chemists to incorporate the observed H-bonding and van der Waals repulsions within the complex as part of the design of newer ligands. The ultimate goal is to have ligands that favor the induction of one cytokine. At this writing, it is not yet understood as to which of the observed bonding and/or repulsion effects are determinative for which cytokine. A planned outcome of the symposium discussions is a better understanding of these details.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
U.S.-Federal Republic of Germany Cooperative Research: Synthesis of Olivomycin A
  • 批准号:
    8712570
  • 项目类别:
    Standard Grant
  • 资助金额:
    $0.74万
  • 财政年份:
    1988
  • 负责人:
    Richard Franck
  • 依托单位:
海外基金